|
|
Central nervous system agent
|
|
Antidepressant
|
|
Depression, Panic Disorder, post-traumatic stress disorder in adults; obsessive-compulsive disorder in adults and children >6 years.
|
|
(Adults) Initially 25-50 mg once daily. Max 200 mg/day. (Children 6 to 12 years) Initially 25 mg once daily. (Children 13 to 17 years) Initially 50 mg once daily. Max 200 mg/day, before or after meals.
|
|
Category B
|
|
Upset stomach, tremors, dizziness, Insomnia, sweating, dry mouth, paresthesia, agitation, hot flashes, loose stools, polyuris, elevated liver enzyme levels, minor increases in serum cholesterol and triglycerides, myalgia, diaphoresis.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
|
|
|